• admin@sclerose.info
Dansk DA English EN Español ES

Press release from Merck

September 12, 2019 Real-world data supports MAVENCLAD® long-term efficacy and adverse event profile • Post-hoc analysis shows that 75% of MAVENCLAD® patients from CLARITY and CLARITY EXTENSION did not experience disease progression five years after treatment • Side effect follow-up from 10 years of clinical studies and data collected since the 2017 marketing authorization shows no new safety findings • MAVENCLAD® is now approved

Read More »

The medicine system works as it should, Jakob Kjellberg says about the medicine council that rejected ocrelizumab for progressive sclerosis

Follow the link to the full article on Sunhedspolitisktidsskrift http://sundhedspolitisktidsskrift.dk/nyheder/1057-jakob-kjellberg-om-afvisning-af-medicin-ssystem-virker-som-det-skal.html d. 13 June Speech by chairman Kim Gelser I can not sit this article over flax. I'm really so angry about this decision - and I'm getting a little mad at Jakob Kjellberg !! No !!!! Jakob Kjellberg is not right !! It's ok that

Read More »

The Board of Medicine rejects ocrelizumab for progressive sclerosis

June 1, 2018 by President Kim Gelser: I'm totally speechless - and I'm damn mad !!! (excuse my French!) The much-talked-about and long-awaited drug for the treatment of primary progressive sclerosis was not approved by the Medicines Council yesterday. ocrelizumab is approved by both the US and the European Medicines Agency, but

Read More »

Genzyme Press Release

CAMBRIDGE, Mass. - October 31, 2012 - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today the publication of results from the LEMTRADA ™ (alemtuzumab) CARE-MS I and CARE-MS II pivotal studies in patients with relapsing remitting multiple sclerosis (MS) in the November 1, 2012, online issue of The Lancet.

Read More »

Press release

Genzyme Corporation (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc. today announced study results showing that patients with early relapsing-remitting multiple sclerosis (RRMS) taking once-yearly cycles of alemtuzumab reduced their risk of relapse by 74 percent and the risk of sustained accumulation of disability by 71 percent compared to patients treated with the active comparator Rebif®

Read More »